Healthcare >> CEO Interviews >> August 6, 2001
DR. HARRY A. DUGGER, III is the President and CEO of Flemington
Pharmaceutical Corp. Dr. Dugger was the founder of Flemington
Pharmaceutical Corp. and the inventor of the lingual spray and bite
capsule technology, which the company is developing and marketing as
Immediate-Immediate Release (I2R)'. Dr. Dugger received his PhD from the
University of Michigan and was an NIH Postdoctoral Fellow at the
University Of Zurich working on the chemical structure of the colors in
red beets and on pseudo-aromatic compounds. He joined Sandoz
Pharmaceuticals in the USA in 1964, where he was responsible for drug
development primarily in the areas of biopharmaceuticals and drug
metabolism. In 1980 he resigned to join a Baurs-Krey Associates in New
York, and in 1983 he founded Pharmaconsult, the precursor to Flemington.
Through Pharmaconsult Dr. Dugger advised clients on all aspects of drug
development, including but not limited to manufacturing of drug
substances and drug products (cGMP), toxicity studies, clinical trails,
filing of ANDAs, INDs NDAs as well as co-founding LAB Inc. in the USA to
market the clinical services of LAB GmbH (Germany) to the US based
pharmaceutical companies. Since 1996 Dr. Dugger has spent much of his
time in developing a number of the I2R formulations and running studies
to demonstrate their utility. Profile
Flemington Pharmaceutical Corporation?
Dr. Dugger: The company was founded in 1982 as a consulting company
under the name of
